Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex

Psychopharmacology

Volumn 230, Issue 3, 2013, Pages 345-352

  Kadowaki Horita, Takako ^a   Kobayashi, Minoru ^a   Mori, Akihisa ^a   Jenner, Peter ^b   Kanda, Tomoyuki ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adenosine A2A receptor; Cognition; Dopamine; Istradefylline; Working memory

Indexed keywords

ADENOSINE A2A RECEPTOR; DONEPEZIL; DOPAMINE; ISTRADEFYLLINE; METHAMPHETAMINE; OXIDOPAMINE; ADENOSINE A2 RECEPTOR ANTAGONIST; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE; PURINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; COGNITION; COGNITIVE DEFECT; DOPAMINE BRAIN LEVEL; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; IN VIVO STUDY; MALE; MEMORY DISORDER; MENTAL TASK; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; WORKING MEMORY; ANIMAL; DISEASE MODEL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SHORT TERM MEMORY; SPRAGUE DAWLEY RAT;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOPAMINE; INDANS; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; METHAMPHETAMINE; OXIDOPAMINE; PIPERIDINES; PREFRONTAL CORTEX; PURINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84888646094     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3158-x     Document Type: Article

References (57)

1. Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 20:1255-1263
2. Acquas E, Tanda G, Chiara GD (2002) Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. Neuropsychopharmacology 27:182-193
3. 2A receptor antagonist KW-6002 and its effect on gene expression in the rat brain. Brain Res 953:119-125
4. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis CA, Davis JG, Moore RY, Dekosky ST (2006) Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 253:242-247
5. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS (1979) Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205:929-932
6. Chaudhuri KR, Schapira AHV (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464-474
7. Clinton SM, Sucharski IL, Finlay JM (2006) Desipramine attenuates working memory impairments induced by partial loss of chtecholamines in the rat medial prefrontal cortex. Psychopharmacology 183:404-412
8. 2A receptors in the modulation of LTP in the rat hippocampus upon ageing. Eur J Neurosci 34:12-21
9. Cuadra G, Summers K, Giacobini E (1994) Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J Pharmacol Exp Ther 270:277-284
10. Decamp E, Schneider JS (2004) Attention and executive function deficits in chronic low dose MPTP-treated non-human primates. Eur J Neurosci 20:1371-1378
11. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC (1996) Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118:1461-1468
12. Dubois B, Pillon B (1997) Cognitive deficits in Parkinson's disease. J Neurol 244:2-8
13. Ennaceur A, Meliani K (1992) A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs. non-spatial working memory. Behav Brain Res 51:83-92
14. Floresco SB, Magyar O (2006) Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology 188:567-585
15. Fraser CM, Fisher A, Cooke MJ, Thompson ID, Stone TW (1997) Purine modulation of dizocilpine effects on spontaneous alternation. Psychopharmacology 130:334-342
16. Giacobini E, Zhu XD, Williams E, Sherman K (1996) The effect of the selective reversible acetylcholinesterase inhibitor E200 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 35:205-211
17. 2A receptors in the brain. Neurobiol Learn Mem 87:42-56
18. Izaki Y, Maruki K, Hori K, Nomura M (2001) Effects of rat medial prefrontal cortex temporal inactivation on a delayed alternation task. Neurosci Lett 315:129-132
19. 2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 14:729-738
20. 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 15:406-413
21. 2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162:321-327
22. Kehagia AA, Barker RA, Robbins TW (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 9:1200-1213
23. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 408:249-255
24. 2 receptor antagonists. Psychopharmacology 146:325-329
25. Liang YQ, Tang XC (2006) Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacol Sin 27:1127-1136
26. 2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 84:1398-1410
27. McKinlay A, Grace RC (2011) Characteristic of cognitive decline in Parkinson's disease: a 1-year follow-up. Appl Neuropsychol 18:269-277
28. 2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H) -one (ASP5854), in models of parkinson's disease and cognition. J Pharmacol Exp Ther 323:708-719
29. 11C]TMSX PET. Synapse 61:778-784
30. Mizoguchi K, Shoji H, Tanaka Y, Murayama W, Tabira T (2009) Age-related spatial working memory impairment is caused by prefrontal cortical dopaminergic dysfunction in rats. Neuroscience 162:1192-1201
31. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M, Japanese Istradefylline Study Group (2010) Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord 25:1437-1443
32. 2A antagonists. Neurology 61:S44-S48
33. Mumby DG (2001) Perspectives on object-recognition memory following hippocampal damage: lessons from studies in rats. Behav Brain Res 127:159-181
34. 2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine- lesioned rats: a microdialysis study. Neuroscience 100:53-62
35. 2A antagonist KW-6002 on reversal learning in rats. Neurobiol Learn Mem 88:75-81
36. Pagonabarraga J, Kulisevsky J (2012) Cognitive impairment and dementia in Parkinson's disease. Neurobiol Dis 46:590-596
37. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, New York
38. Pereira GS, Rossato JI, Sarkis JJ, Cammarota M, Bonan CD, Izquierdo I (2005) Activation of adenosine receptors in the posterior cingulate cortex impairs memory retrieval in the rat. Neurobiol Learn Mem 83:217-223
39. 2A receptors. Neurosci Lett 376:160-165
40. 2 receptors modulates the social recognition memory in reserpine-treated rats. Behav Pharmacol 16:209-218
41. 2A receptors. Neurobiol Aging 26:957-964
42. 2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats. Behav Brain Res 159:197-205
43. Richard IH, Justus AW, Greig NH, Marshall F, Kurlan R (2002) Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol 25:296-299
44. 18F]fluorodopa positron emission tomographic study. Arch Neurol 57:470-475
45. Sánchez-Santed F, de Bruin JP, Heinsbroek RP, Verwer RW (1997) Spatial delayed alternation of rats in a T-maze: effects of neurotoxic lesions of the medial prefrontal cortex and of T-maze rotations. Behav Brain Res 84:73-79
46. Sawada Y, Nishio Y, Suzuki K, Hirayama K, Takeda A, Hosokai Y, Ishioka T, Itoyama Y, Takahashi S, Fukuda H, Mori E (2012) Attentional set-shifting deficit in Parkinson's disease is associated with prefrontal dysfunction: an FDG-PET study. PLoS One 7:e38498
47. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275:321-328
48. Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson's disease? J Neurol Nerurosurg Psyhiatry 69:308-312
49. Sherman E, Rossi S, Szasz B, Juranyi Z, Fallon S, Pomara N, Sershen H, Lajtha A (2006) Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Bran Res Bull 69:204-213
50. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 147:90-95
51. Takahashi RN, Pamplona FA, Prediger RDS (2008) Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci 13:2614-2632
52. van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE (2011) Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data. CNS Neurosci Ther 17:428-441
53. Ventura R, Pascucci T, Catania MV, Musumeci SA, Puglisi-Allegra S (2004) Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex. Behav Pharmacol 15:433-442
54. 2A receptors. Exp Neurol 199:438-445
55. Watanabe M, Kodama T, Hirosaka K (1997) Increase of extracellular dopamine in primate prefrontal cortex during a working memory task. J Neurophysiol 78:2795-2798
56. Wei CJ, Li W, Chen J-F (2011) Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim Biophys Acta 1808:1358-1379
57. 2A receptors. Brain Res 1303:74-83